Agenus Receives $20 Million Contingent Payment From Zydus Lifesciences Collaboration
MT Newswires Live
Mar 10
Agenus (AGEN) said Tuesday it has received a $20 million milestone payment from Zydus Lifesciences as part of strategic deal to accelerate development of botensilimab and balstilimab to treat immune-resistant tumors.
The company said the payment was triggered by contracted work orders for critical chemistry, manufacturing and controls, and production activities related to botensilimab and balstilimab.
Under the agreement, Agenus could be entitled to as much as $50 million in milestone payments that could be triggered by botensilimab and balstilimab production orders, the company said.
Shares of Agenus were up 1.3% pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.